Blog Posts

FDA Oncology – Overall Survival and PARP Inhibitors in Advanced Ovarian Cancer

Source: Depositphotos

May 28, 2025, 07:50

FDA Oncology – Overall Survival and PARP Inhibitors in Advanced Ovarian Cancer

FDA Oncology posted on X:

“FDA article outlines the decision-making process and rationale behind removal or narrowing of certain indications for PARP inhibitors in treatment of advanced ovarian cancer – via Journal of Clinical Oncology.”

Title: Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer

Authors: Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H. Fiero, Hui Zhang, Xin Gao, Marc Neilson, Kirsten B. Goldberg, Abhilasha Nair, Tiffany K. Ricks, William F. Pierce, Nicole Gormley, Marc R. Theoret, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri-Kordestani

Read The Full Article at ASCO Publications.

FDA Oncology - Overall Survival and PARP Inhibitors in Advanced Ovarian Cancer

More posts featuring Ovarian Cancer.

Abhilasha Nair cancer FDA Oncology Gwynn Ison Hui Zhang Journal of Clinical Oncology Kirsten B. Goldberg Laleh Amiri-Kordestani Mallorie H. Fiero Marc Neilson Marc R. Theoret Mirat Shah Nicole Gormley OncoDaily Oncology Ovarian Cancer Paul G Kluetz Richard Pazdur Shenghui Tang Tiffany K. Ricks Ting-Yu Chen William F. Pierce Xin Gao

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth